Progression of brain cholinergic dysfunction in patients with isolated rapid eye movement sleep behavior disorder.
Parkinson's disease
REM sleep behavior disorder
biomarkers
cognition
positron emission tomography
Journal
European journal of neurology
ISSN: 1468-1331
Titre abrégé: Eur J Neurol
Pays: England
ID NLM: 9506311
Informations de publication
Date de publication:
Jan 2024
Jan 2024
Historique:
revised:
25
09
2023
received:
19
04
2023
accepted:
27
09
2023
pubmed:
17
10
2023
medline:
17
10
2023
entrez:
17
10
2023
Statut:
ppublish
Résumé
Reduced cortical acetylcholinesterase activity, as measured by Twelve iRBD patients underwent From baseline to follow-up, the mean Our results show that severity of brain cholinergic dysfunction in iRBD patients increases significantly over 3 years, and those changes are more severe in those with a decline in cognitive test scores.
Sections du résumé
BACKGROUND
BACKGROUND
Reduced cortical acetylcholinesterase activity, as measured by
METHODS
METHODS
Twelve iRBD patients underwent
RESULTS
RESULTS
From baseline to follow-up, the mean
CONCLUSIONS
CONCLUSIONS
Our results show that severity of brain cholinergic dysfunction in iRBD patients increases significantly over 3 years, and those changes are more severe in those with a decline in cognitive test scores.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e16101Subventions
Organisme : Danish Parkinson's Association
Organisme : Danmarks Frie Forskningsfond
Organisme : Instituto de Salud Carlos III
Informations de copyright
© 2023 The Authors. European Journal of Neurology published by John Wiley & Sons Ltd on behalf of European Academy of Neurology.
Références
Iranzo A, Santamaria J, Tolosa E. Idiopathic rapid eye movement sleep behaviour disorder: diagnosis, management, and the need for neuroprotective interventions. Lancet Neurol 2016;15(4):405-419. doi:10.1016/S1474-4422(16)00057-0
Hogl B, Stefani A, Videnovic A. Idiopathic REM sleep behaviour disorder and neurodegeneration - an update. Nat Rev Neurol. 2018;14(1):40-55. doi:10.1038/nrneurol.2017.157
Postuma RB. Prodromal Parkinson's disease-using REM sleep behavior disorder as a window. Parkinsonism Relat Disord. 2014;20(Suppl. 1):S1-S4. doi:10.1016/S1353-8020(13)00400-8
Youn S, Kim T, Yoon IY, et al. Progression of cognitive impairments in idiopathic REM sleep behaviour disorder. J Neurol Neurosurg Psychiatry. 2016;87(8):890-896. doi:10.1136/jnnp-2015-311437
Yoo D, Lee JY, Kim YK, et al. Mild cognitive impairment and abnormal brain metabolic expression in idiopathic REM sleep behavior disorder. Parkinsonism Relat Disord. 2021;90:1-7. doi:10.1016/j.parkreldis.2021.07.022
Fereshtehnejad SM, Yao C, Pelletier A, Montplaisir JY, Gagnon JF, Postuma RB. Evolution of prodromal Parkinson's disease and dementia with Lewy bodies: a prospective study. Brain. 2019;142(7):2051-2067. doi:10.1093/brain/awz111
Bourgouin PA, Rahayel S, Gaubert M, et al. Neuroimaging of rapid eye movement sleep behavior disorder. Int Rev Neurobiol. 2019;144:185-210. doi:10.1016/bs.irn.2018.10.006
Gersel Stokholm M, Iranzo A, Ostergaard K, et al. Cholinergic denervation in idiopathic rapid eye movement sleep behaviour disorder patients. Eur J Neurol. 2019;27:644-652. doi:10.1111/ene.14127
Nasreddine ZS, Phillips NA, Bedirian V, et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc. 2005;53(4):695-699. doi:10.1111/j.1532-5415.2005.53221.x
Staer K, Iranzo A, Stokholm MG, et al. Cortical cholinergic dysfunction correlates with microglial activation in the substantia innominata in REM sleep behavior disorder. Parkinsonism Relat Disord. 2020;81:89-93. doi:10.1016/j.parkreldis.2020.10.014
Colloby SJ, Elder GJ, Rabee R, O'Brien JT, Taylor JP. Structural grey matter changes in the substantia innominata in Alzheimer's disease and dementia with Lewy bodies: a DARTEL-VBM study. Int J Geriatr Psychiatry. 2017;32(6):615-623. doi:10.1002/gps.4500
Hanyu H, Asano T, Sakurai H, Tanaka Y, Takasaki M, Abe K. MR analysis of the substantia innominata in normal aging, Alzheimer disease, and other types of dementia. AJNR Am J Neuroradiol. 2002;23(1):27-32.
Weil RS, Lashley TL, Bras J, Schrag AE, Schott JM. Current concepts and controversies in the pathogenesis of Parkinson's disease dementia and dementia with Lewy bodies. F1000Res. 2017;6:1604. doi:10.12688/f1000research.11725.1
American Academy of Sleep Medicine. International Classification of Sleep Disorders. 3rd ed. American Academy of Sleep Medicine; 2014.
Goetz CG, Tilley BC, Shaftman SR, et al. Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord. 2008;23(15):2129-2170. doi:10.1002/mds.22340
Folstein MF, Folstein SE, McHugh PR. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12(3):189-198. doi:10.1016/0022-3956(75)90026-6
Chaudhuri KR, Martinez-Martin P, Brown RG, et al. The metric properties of a novel non-motor symptoms scale for Parkinson's disease: results from an international pilot study. Mov Disord. 2007;22(13):1901-1911. doi:10.1002/mds.21596
McKeith IG, Boeve BF, Dickson DW, et al. Diagnosis and management of dementia with Lewy bodies: fourth consensus report of the DLB consortium. Neurology. 2017;89(1):88-100. doi:10.1212/WNL.0000000000004058
Gilman S, Wenning GK, Low PA, et al. Second consensus statement on the diagnosis of multiple system atrophy. Neurology. 2008;71(9):670-676. doi:10.1212/01.wnl.0000324625.00404.15
Albert MS, DeKosky ST, Dickson D, et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011;7(3):270-279. doi:10.1016/j.jalz.2011.03.008
American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th ed. American Psychiatric Association; 2013.
Stiasny-Kolster K, Mayer G, Schafer S, Moller JC, Heinzel-Gutenbrunner M, Oertel WH. The REM sleep behavior disorder screening questionnaire-a new diagnostic instrument. Mov Disord. 2007;22(16):2386-2393. doi:10.1002/mds.21740
Logan J, Fowler JS, Volkow ND, Wang GJ, Ding YS, Alexoff DL. Distribution volume ratios without blood sampling from graphical analysis of PET data. J Cereb Blood Flow Metab. 1996;16(5):834-840. doi:10.1097/00004647-199609000-00008
Hammers A, Allom R, Koepp MJ, et al. Three-dimensional maximum probability atlas of the human brain, with particular reference to the temporal lobe. Hum Brain Mapp. 2003;19(4):224-247. doi:10.1002/hbm.10123
Zaborszky L, Hoemke L, Mohlberg H, Schleicher A, Amunts K, Zilles K. Stereotaxic probabilistic maps of the magnocellular cell groups in human basal forebrain. Neuroimage. 2008;42(3):1127-1141. doi:10.1016/j.neuroimage.2008.05.055
Postuma RB, Berg D, Stern M, et al. MDS clinical diagnostic criteria for Parkinson's disease. Mov Disord. 2015;30(12):1591-1601. doi:10.1002/mds.26424
Bohnen NI, Muller ML, Koeppe RA, et al. History of falls in Parkinson disease is associated with reduced cholinergic activity. Neurology 2009;73(20):1670-1676. doi:10.1212/WNL.0b013e3181c1ded6
Horsager J, Andersen KB, Knudsen K, et al. Brain-first versus body-first Parkinson's disease: a multimodal imaging case-control study. Brain. 2020;143(10):3077-3088. doi:10.1093/brain/awaa238
Bedard MA, Aghourian M, Legault-Denis C, et al. Brain cholinergic alterations in idiopathic REM sleep behaviour disorder: a PET imaging study with (18)F-FEOBV. Sleep Med. 2019;58:35-41. doi:10.1016/j.sleep.2018.12.020
Lessig S, Nie D, Xu R, Corey-Bloom J. Changes on brief cognitive instruments over time in Parkinson's disease. Mov Disord. 2012;27(9):1125-1128. doi:10.1002/mds.25070
Biundo R, Weis L, Bostantjopoulou S, et al. MMSE and MoCA in Parkinson's disease and dementia with Lewy bodies: a multicenter 1-year follow-up study. J Neural Transm (Vienna). 2016;123(4):431-438. doi:10.1007/s00702-016-1517-6
Greenfield SA. A noncholinergic action of acetylcholinesterase (AChE) in the brain: from neuronal secretion to the generation of movement. Cell Mol Neurobiol. 1991;11(1):55-77. doi:10.1007/BF00712800
Kato K, Hayako H, Ishihara Y, Marui S, Iwane M, Miyamoto M. TAK-147, an acetylcholinesterase inhibitor, increases choline acetyltransferase activity in cultured rat septal cholinergic neurons. Neurosci Lett. 1999;260(1):5-8. doi:10.1016/s0304-3940(98)00943-4
Siddiqui T, Bhatt LK. Targeting sigma-1 receptor: a promising strategy in the treatment of Parkinson's disease. Neurochem Res. 2023;48(10):2925-2935. doi:10.1007/s11064-023-03960-6
Kuhl DE, Minoshima S, Fessler JA, et al. In vivo mapping of cholinergic terminals in normal aging, Alzheimer's disease, and Parkinson's disease. Ann Neurol. 1996;40(3):399-410. doi:10.1002/ana.410400309